# Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A Adults

> **NCT04370054** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Pfizer** · enrollment: 77 (actual)

## Conditions studied

- Hemophilia A

## Interventions

- **BIOLOGICAL:** PF-07055480 (giroctocogene fitelparovec): Recombinant AAV2/6 Human Factor VIII Gene Therapy

## Key facts

- **NCT ID:** NCT04370054
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-08-18
- **Primary completion:** 2024-06-17
- **Final completion:** 2026-10-25
- **Target enrollment:** 77 (ACTUAL)
- **Last updated:** 2026-05-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04370054

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04370054, "Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A Adults". Retrieved via AI Analytics 2026-09-06 from https://api.ai-analytics.org/clinical/NCT04370054. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*